NCT05194995 2026-03-16JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationAllist Pharmaceuticals, Inc.Phase 1/2 Active not recruiting48 enrolled
NCT06128551 2026-02-10Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1/2 Recruiting534 enrolled
NCT04902872 2025-01-23Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid TumorsCybrexa TherapeuticsPhase 1/2 Active not recruiting130 enrolled